Tubulin Binding agent: Interim Phase I data

In a Phase I trial in 27 patients with advanced cancer, dose limiting toxicity for oral ENMD-1198 was established at 550 mg/m 2/day with 2 cases of grade 4 neutropenia. Four patients have experienced ...